Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth.
Disscusion boards licensed and powered by ZoneX v3.3.1 Development supported by LifeForm Inc.
All Rights Reserved by SteadyHealth.com
© 2004 - 2009
This site complies with the HONcode standard for trustworthy health information:
verify here.
